Abstract Details

Title Preliminary Results of the Phase I Clinical Study Evaluating Neural Stem Cell Based Therapy for Parkinson's Disease

Topic Movement Disorders

Presentation(s) S4 - (-)

Poster/Presentation
Number 004

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Russell A. Kern, PhD (International Stem Cell Corporation) PRESENTER	No disclosure on file
Ibon Garitaonandia (International Stem Cell Corporation)	No disclosure on file
Rodolfo Gonzalez	No disclosure on file
	No disclosure on file
	No disclosure on file
Evan Y. Snyder, MD, PhD (The Burn Institute)	No disclosure on file
	No disclosure on file
	No disclosure on file
Andrew H. Evans, MB, BS	Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stada. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Seqirus. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Stada. The institution of Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Ipsen. Mr. Evans has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Seqirus.

��ɫ��